Targeted biologics, the recent emergence of innovative new oral therapies and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.
In Immunology SGI focus on three key areas; Rheumatology, Dermatology and Gastroenterology, aiming to provide insight and answer critical questions such as….Which are the more dynamic brands across key auto-immune indications and why? How quickly are immune specialists adopting newly approved and novel treatments? What hopes and aspirations do prescribers have for novel MOAs? How do new approvals challenge the current treatment algorithm? How do perception of manufacturers and brand promotional activity influence prescribing behavior?
Direct from our Research!
RA patients are ACTIVE in their treatment decisions! In patients recently switched from one biologic/Xeljanz brand to another, and patients were involved in the switch decision 93% of the time.
A hot new treatment option for psoriasis! At just over one month post-launch, one-third of dermatologists reported trialing Taltz, Eli Lilly’s newly launched IL-17 inhibitor.
Where will JAK’s fit in the treatment of IBD? Gastroenterologists believe Pfizer’s oral JAK inhibitor, Xeljanz, will be highly favored by their IBD patients.